<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233535">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034983</url>
  </required_header>
  <id_info>
    <org_study_id>2006_407</org_study_id>
    <secondary_id>Formally-497B</secondary_id>
    <secondary_id>MK0869-066</secondary_id>
    <nct_id>NCT00034983</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Major Depressive Disorder With MK0869</brief_title>
  <official_title>A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A clinical study to determine the efficacy and safety of an investigational medication
      (MK0869) in the treatment of depression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of treatment is 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term safety and tolerability.</measure>
    <time_frame>Duration of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences</measure>
    <time_frame>Duration of treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">900</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <other_name>MK0869</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: paroxetine HCL</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Depressive Disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2008</verification_date>
  <lastchanged_date>July 31, 2008</lastchanged_date>
  <firstreceived_date>May 2, 2002</firstreceived_date>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
